Praxis Precision Medicines (PRAX) Gets a Buy from Chardan Capital
I'm PortAI, I can summarize articles.
Praxis Precision Medicines (PRAX) received a Buy rating and a $330 price target from Chardan Capital analyst Rudy Li. The stock closed at $294.74. Li, who covers the Healthcare sector, has an average return of 66.1% and a 57.14% success rate. The analyst consensus for Praxis is Strong Buy, with a price target consensus of $445.50, indicating a 51.15% upside. TD Cowen also maintained a Buy rating with a $353 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments